NASDAQ:CVAC CureVac (CVAC) Stock Price, News & Analysis $2.98 +0.18 (+6.43%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$3.02 +0.04 (+1.34%) As of 03/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About CureVac Stock (NASDAQ:CVAC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CureVac alerts:Sign Up Key Stats Today's Range$2.97▼$3.3350-Day Range$2.80▼$4.1452-Week Range$2.22▼$5.28Volume2.03 million shsAverage Volume817,977 shsMarket Capitalization$667.16 millionP/E Ratio5.42Dividend YieldN/APrice Target$10.00Consensus RatingHold Company OverviewCureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Read More… Remove Ads CureVac Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreCVAC MarketRank™: CureVac scored higher than 76% of companies evaluated by MarketBeat, and ranked 239th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingCureVac has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageCureVac has only been the subject of 1 research reports in the past 90 days.Read more about CureVac's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CureVac are expected to decrease in the coming year, from $0.72 to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CureVac is 5.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.58.Price to Earnings Ratio vs. SectorThe P/E ratio of CureVac is 5.42, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.60.Price to Book Value per Share RatioCureVac has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CureVac's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.34% of the float of CureVac has been sold short.Short Interest Ratio / Days to CoverCureVac has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in CureVac has recently increased by 3.84%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCureVac does not currently pay a dividend.Dividend GrowthCureVac does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-2.34 Percentage of Shares Shorted4.34% of the float of CureVac has been sold short.Short Interest Ratio / Days to CoverCureVac has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in CureVac has recently increased by 3.84%, indicating that investor sentiment is decreasing. News and Social Media2.6 / 5News Sentiment0.61 News SentimentCureVac has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for CureVac this week, compared to 3 articles on an average week.Search Interest7 people have searched for CVAC on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CureVac insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.15% of the stock of CureVac is held by insiders.Percentage Held by InstitutionsOnly 17.26% of the stock of CureVac is held by institutions.Read more about CureVac's insider trading history. Receive CVAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter. Email Address CVAC Stock News Headlines12 Best German Stocks to Buy According to Hedge FundsMarch 30 at 7:39 AM | insidermonkey.comCureVac’s amended patent upheld by European Patent OfficeMarch 29 at 1:41 AM | investing.comTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.March 30, 2025 | Porter & Company (Ad)Lululemon, General Motors and Apple fall premarket; CureVac gainsMarch 28 at 8:40 PM | investing.comCureVac says European Patent Office dismissed BioNTech oppositionMarch 28 at 8:40 PM | markets.businessinsider.comEuropean Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock JumpsMarch 28 at 9:46 AM | benzinga.comCureVac (CVAC) Surges as European Court Validates Key PatentMarch 27 at 6:49 PM | gurufocus.comEuropean Patent Office declares CureVac mRNA patent validMarch 27 at 6:22 PM | reuters.comSee More Headlines CVAC Stock Analysis - Frequently Asked Questions How have CVAC shares performed this year? CureVac's stock was trading at $3.41 at the beginning of the year. Since then, CVAC stock has decreased by 12.6% and is now trading at $2.98. View the best growth stocks for 2025 here. How were CureVac's earnings last quarter? CureVac (NASDAQ:CVAC) posted its earnings results on Sunday, November, 29th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($54.37) by $54.13. CureVac had a net margin of 20.72% and a trailing twelve-month return on equity of 21.98%. When did CureVac IPO? CureVac (CVAC) raised $200 million in an initial public offering (IPO) on Friday, August 14th 2020. The company issued 13,300,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse served as the underwriters for the IPO and Berenberg and Kempen were co-managers. Who are CureVac's major shareholders? Top institutional shareholders of CureVac include Millennium Management LLC (0.74%), Alyeska Investment Group L.P. (0.22%), Point72 Asset Management L.P. (0.20%) and DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main (0.11%). How do I buy shares of CureVac? Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CureVac own? Based on aggregate information from My MarketBeat watchlists, some other companies that CureVac investors own include NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA), NIO (NIO), Advanced Micro Devices (AMD), Meta Platforms (META) and Moderna (MRNA). Company Calendar Last Earnings11/29/2020Today3/30/2025Next Earnings (Estimated)4/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CVAC CIK1809122 Webwww.curevac.com Phone49-70-71988-30Fax49-7071-9883Employees880Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$16.00 Low Stock Price Target$4.00 Potential Upside/Downside+235.6%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.55 Trailing P/E Ratio5.42 Forward P/E Ratio4.14 P/E GrowthN/ANet Income$-281,580,000.00 Net Margins20.72% Pretax Margin27.11% Return on Equity21.98% Return on Assets15.72% Debt Debt-to-Equity Ratio0.05 Current Ratio6.20 Quick Ratio6.19 Sales & Book Value Annual Sales$543.28 million Price / Sales1.23 Cash FlowN/A Price / Cash FlowN/A Book Value$2.50 per share Price / Book1.19Miscellaneous Outstanding Shares223,880,000Free Float219,067,000Market Cap$667.16 million OptionableOptionable Beta2.53 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CVAC) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.